Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Chem|
|Published species reactivity||Rat|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Bromodeoxyuridine conjugated to BSA.|
|Storage buffer||PBS, pH 7.4|
|Contains||0.09% sodium azide|
|Storage Conditions||4°C or -20°C if preferred|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1/25 -1/100|
|Immunohistochemistry (Paraffin, Frozen) (IHC (P, F))||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
For FACS analysis, use 10ul of the suggested working dilution to label 1x10^6 cells in 100ul.
Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) is a synthetic nucleoside that is an analogue of thymidine. BrdU is commonly used in the detection of proliferating cells in living tissues. BrdU can be incorporated into the newly synthesized DNA of replicating cells (during the S phase of the cell cycle), substituting for thymidine during DNA replication. Antibodies specific for BrdU can then be used to detect the incorporated chemical, thus indicating cells that were actively replicating their DNA. Binding of the antibody requires denaturation of the DNA, usually by exposing the cells to acid or heat.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine.
MA1-81890 was used in immunohistochemistry to study the effect of exogenous glucagon-like peptide-2 on chemotherapy-induced mucositis in rat small intestine
|Kissow H,Viby NE,Hartmann B,Holst JJ,Timm M,Thim L,Poulsen SS||Cancer chemotherapy and pharmacology (70:39)||2012|